

1 **Genomic Sequencing for Newborn Screening: Results of the NC NEXUS Project**

2 Tamara S. Roman<sup>1</sup>, Stephanie B. Crowley<sup>1</sup>, Myra I. Roche<sup>1,2</sup>, Ann Katherine M. Foreman<sup>1</sup>,  
3 Julianne M. O'Daniel<sup>1</sup>, Bryce A. Seifert<sup>1</sup>, Kristy Lee<sup>1</sup>, Alicia Brandt<sup>1</sup>, Chelsea Gustafson<sup>1</sup>,  
4 Daniela M. DeCristo<sup>1</sup>, Natasha T. Strande<sup>3</sup>, Lori Ramkissoon<sup>3</sup>, Laura V. Milko<sup>1</sup>, Phillips Owen<sup>4</sup>,  
5 Sayanty Roy<sup>3</sup>, Mai Xiong<sup>3</sup>, Ryan S. Paquin<sup>5</sup>, Rita M. Butterfield<sup>6</sup>, Megan A. Lewis<sup>5</sup>, Katherine J.  
6 Souris<sup>7</sup>, Donald B. Bailey Jr.<sup>8</sup>, Christine Rini<sup>9</sup>, Jessica K. Booker<sup>1,3</sup>, Bradford C. Powell<sup>1</sup>, Karen  
7 E. Weck<sup>1,3</sup>, Cynthia M. Powell<sup>1,2,10</sup>, Jonathan S. Berg<sup>1,10\*</sup>

- 8 1. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC  
9 27599
- 10 2. Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine  
11 Chapel Hill, NC 27599
- 12 3. Department of Pathology and Laboratory Medicine, The University of North Carolina at  
13 Chapel Hill, Chapel Hill, NC 27599
- 14 4. Renaissance Computing Institute, Chapel Hill, NC 27517
- 15 5. Center for Communication Science, RTI International, Research Triangle Park, NC  
16 27709
- 17 6. Department of Family Medicine and Community Health, Duke University School of  
18 Medicine, Durham, NC 27705
- 19 7. Department of Health Behavior, Gillings School of Global Public Health, University of  
20 North Carolina at Chapel Hill, Chapel Hill, NC 27599
- 21 8. Center for Newborn Screening, Ethics and Disability Studies, RTI International,  
22 Research Triangle Park, NC 27709
- 23 9. Feinberg School of Medicine, Department of Medical Social Sciences, and the Robert H.  
24 Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611
- 25 10. These authors contributed equally to this work

26 \*Corresponding author: jonathan\_berg@med.unc.edu

27

28 **Abstract:**

29 Newborn screening (NBS) was established as a public health program in the 1960's and is  
30 crucial for facilitating detection of certain medical conditions in which early intervention can  
31 prevent serious, life-threatening health problems. Genomic sequencing can potentially expand  
32 the screening for rare hereditary disorders, but many questions surround its possible use for this  
33 purpose. We examined the use of exome sequencing (ES) for NBS  
34 in the North Carolina Newborn Exome Sequencing for Universal Screening (NC NEXUS) project,  
35 comparing the yield from ES used in a screening versus a diagnostic context. We enrolled  
36 healthy newborns and children with metabolic diseases or hearing loss (106 participants total).  
37 ES confirmed the participant's underlying diagnosis in 15 out of 17 (88%) children with  
38 metabolic disorders, and in 5 out of 28 (~18%) children with hearing loss.  
39 We discovered actionable findings in 4 participants that would not have been detected by  
40 standard NBS. A subset of parents was eligible to receive additional information for their child  
41 about childhood-onset conditions with low or no clinical actionability, clinically actionable adult-  
42 onset conditions, and carrier status for autosomal recessive conditions. We found pathogenic  
43 variants associated with hereditary breast and/or ovarian cancer in 2 children, a  
44 likely pathogenic variant in the gene associated with Lowe syndrome in one child, and an  
45 average of 1.8 reportable variants per child for carrier results. These results highlight the  
46 benefits and limitations of using genomic sequencing for NBS and the challenges of using such  
47 technology in future precision medicine approaches.

48

49

50

51 **Introduction:**

52 Newborn screening was established in the early 1960's, beginning with phenylketonuria<sup>1</sup>  
53 (PKU) (MIM: 261600), for which early intervention can prevent permanent intellectual disability.  
54 In the 1990's tandem mass spectrometry was employed to efficiently screen neonates for  
55 numerous metabolites, which resulted in an increase in the number of genetic conditions  
56 screened<sup>2-4</sup>. As of July 2018, The American College of Medical Genetics and Genomics and the  
57 United States federal Advisory Committee on Heritable Disorders in Newborns and Children  
58 have identified 35 core conditions and 26 secondary conditions to be included on the  
59 recommended uniform screening panel (RUSP, recommended by the Secretary of the  
60 Department of Health and Human Services), including specific disorders of organic acids, fatty  
61 acid oxidation, amino acids, as well as endocrine and hemoglobin disorders<sup>5-7</sup>. Most infants in  
62 the United States also receive point of care newborn screening for hearing and critical  
63 congenital heart disease.

64 Advances in genomic sequencing technologies (next-generation sequencing, or NGS),  
65 such as exome and genome sequencing (ES or GS, respectively), have emerged as powerful  
66 tools for identifying an individual's genomic changes at the DNA base level<sup>8</sup>. These technologies  
67 have the potential to dramatically increase the ability to screen newborns for rare hereditary  
68 disorders that would not be detected using traditional screening methods. Given this potential,  
69 the National Institute of Child Health and Human Development (NICHD) and the National  
70 Human Genome Research Institute (NHGRI) sponsored a consortium of studies, the Newborn  
71 Sequencing in Genomic Medicine and Public Health (NSIGHT) consortium, to investigate the  
72 use of this technology in newborns<sup>9-12</sup>. One of these studies recently reported on the use of  
73 NGS in healthy newborns and reported additional findings that would have been missed by  
74 existing newborn screening modalities<sup>10</sup>. Thus, for some cases, genomic sequencing may clarify  
75 the underlying genetic cause of an individual's disease and directly impact a patient's diagnosis,

76 intervention and/or treatment. In addition, genomic sequencing may also be useful for screening  
77 asymptomatic individuals.

78 In the North Carolina Newborn Exome Sequencing for Universal Screening (NC NEXUS)  
79 study, we explored the possible use of ES in the context of newborn screening and studied the  
80 responses of parents to this new technology. The study design<sup>13</sup> included two cohorts of infants  
81 and children: 1) healthy newborns whose parents were approached for participation in the study  
82 prenatally; and 2) infants and children (< 5 years of age) already clinically diagnosed with  
83 conditions detected with current newborn screening methods (inborn errors of metabolism and  
84 hearing loss).

85 In the current manuscript, we report the molecular analysis results from the cohort of  
86 106 children who were enrolled in the study. Molecular analysts examined ES data using a next-  
87 generation sequencing newborn screen (NGS-NBS) panel of 466 genes<sup>14</sup>, while being blinded  
88 to the identity of the participant's cohort (well-child, metabolic or hearing loss). In our analysis  
89 strategy, we defined strict criteria for assessing the screen as "positive," which allowed us to  
90 examine the sensitivity of ES when used as a screening test to detect a genetic alteration in the  
91 context of a theoretical newborn screen. For those participants in the metabolic cohort or the  
92 hearing loss cohort, we then performed a second, indication-based, diagnostic analysis  
93 assessing the ES results for additional genes that were likely associated with the participant's  
94 phenotype. In addition, parents were randomized to one of two study arms. In one study arm,  
95 parents could elect to learn additional findings from their child's ES. The results of the initial  
96 NGS-NBS screening, indication-based analyses and additional genomic findings are presented  
97 in this work.

98

99

100

## 101 **Methods**

### 102 **Recruitment and sample collection**

103           The study protocol was approved by the University of North Carolina Institutional Review  
104 Board and all participants were consented to the study by a certified genetic counselor. The NC  
105 NEXUS randomized controlled trial protocol and study design were previously described<sup>13</sup>. As  
106 part of that protocol, 17 children previously diagnosed with inborn errors of metabolism and 28  
107 children previously diagnosed with hearing loss were recruited into the study. Additionally, we  
108 recruited parents in the prenatal period (pregnancies of 18 weeks or longer) in which the fetus  
109 did not have a positive or pending chromosomal abnormality or congenital malformation  
110 diagnostic test result. The mothers subsequently gave birth to 61 infants; these babies were  
111 classified into the well-child cohort. Participant demographic information is reported in  
112 Supplemental Table 1.

113

### 114 **Decision aids**

115           As part of the overall study, we previously described a decision aid for parents who  
116 would be offered ES for their child<sup>13,15</sup>. This web-based electronic decision aid was developed to  
117 enhance parents' abilities to make decisions about learning genomic information for their child;  
118 the aid included both an educational component and a values clarification exercise. The  
119 educational component included information about newborn screening, genomic sequencing  
120 and the process of using genomic sequencing to identify genetic variants associated with  
121 specific diseases. This educational component was followed by a values clarification exercise in  
122 which parents classified 5 reasons for and 5 reasons against having genomic sequencing for  
123 their child by level of importance<sup>15-17</sup>. After viewing the decision aid, parents met face-to-face

124 with a genetic counselor for additional clarification before being asked to decide whether to  
125 consent to ES for their child.

126

127

### 128 **Age-based semi-quantitative metric**

129 As previously described<sup>14</sup>, we determined actionability of gene-disease pairs using the age-  
130 based semi-quantitative metric (ASQM). Conditions were placed into one of four categories:  
131 Category 1: pediatric conditions with high medical actionability; Category 2: pediatric conditions  
132 with low or no medical actionability; Category 3: adult conditions with high medical actionability;  
133 and Category 4: adult conditions with low or no medical actionability. In total, 822 gene-disease  
134 pairs were assessed, enriched for those with pediatric onset of disease and suspected  
135 actionability. Category 1 (466 gene-disease pairs) included many core RUSP conditions, as well  
136 as other disorders with onset in infancy or in childhood that have treatment, monitoring and/or  
137 medical management that can potentially improve clinical outcomes; these conditions are  
138 comparable to those detected by current NBS and therefore all NC NEXUS study participants  
139 were eligible for disclosure of positive findings.

140

### 141 **Randomization for additional findings**

142 Parents were randomized to one of two study arms. One arm was the “Control arm” (1/3  
143 of participants) in which parents learned findings from the NGS-NBS panel and, if applicable,  
144 indication-based analysis. The second arm was the “Decision arm” (2/3 of participants) in which  
145 parents learned findings from the NGS-NBS (and indication-based analysis if applicable) and  
146 were also asked to decide whether or not they wanted to learn about additional types of

147 genomic findings from up to three categories. These three categories included: childhood-onset  
148 conditions with low or no clinical actionability, adult-onset conditions with high actionability, and  
149 carrier status for autosomal recessive disorders.

150

151

## 152 **Exome sequencing**

153 The BioSpecimen Processing Facility at the University of North Carolina at Chapel Hill  
154 isolated genomic DNA from saliva and oral epithelial cell samples using PureGene chemistry.  
155 Exome libraries, including molecular barcoding and exome capture, were prepared using Agilent  
156 SureSelect XT kits (Human All Exon V6 probes) according to the manufacturer's low input  
157 guidelines. The University of North Carolina High-Throughput Sequencing Facility performed  
158 exome sequencing on an Illumina HiSeq2500 with minimum depth of 40X coverage. Raw  
159 sequence reads were mapped to the human genome reference GRCh38.p7 using BWA-MEM  
160 version 0.7.12 (arXiv:1303.3997v1 [q-bio.GN]), duplicate reads were marked using Picard  
161 MarkDuplicates (version 1.130) and variants were called using freebayes, version 1.1.0 (arXiv  
162 preprint arXiv:1207.3907 [q-bio.GN] 2012).

163

## 164 **Bioinformatics and Molecular Analysis**

165 Variants were prioritized based on previous classification as pathogenic (P) or likely  
166 pathogenic (LP) in a ClinVar submission<sup>18</sup>, minor allele frequency in a reference database<sup>19</sup> and  
167 predicted effect of the variant on the protein (frameshift, nonsense, canonical splice-site,  
168 missense, synonymous, intronic variants). All rare possibly damaging variants in 466 genes in  
169 Category 1 were reviewed by a molecular analyst for each of the 106 participants. For the initial

170 NGS-NBS analysis, molecular analysts were blinded to the participant's cohort (metabolic,  
171 hearing loss, or well-child). Variants were classified based on ACMG/AMP interpretation  
172 guidelines<sup>20,21</sup> using collected evidence from population databases, ClinVar<sup>18</sup> and the primary  
173 literature. Pathogenic and/or LP variants that were considered an abnormal, "positive" screen  
174 (heterozygous P/LP variants in a gene associated with a dominant condition; two or more P/LP  
175 variants in a gene associated with a recessive condition) were flagged for further review by a  
176 committee of molecular geneticists and physicians, genetic counselors and researchers.  
177 Variants of uncertain significance (VUS) were not returned in the NGS-NBS screen. After  
178 completion of the first NGS-NBS analysis, the participant's cohort was revealed to the molecular  
179 analyst. If the participant was part of the metabolic cohort or hearing loss cohort, ES data were  
180 further analyzed by filtering for variants in a subset of genes within indication-based "diagnostic  
181 lists," containing genes associated with the relevant phenotypes. For the indication-based  
182 diagnostic analyses, P, LP and VUS were reported. All variants were confirmed in a duplicate  
183 sample using an orthogonal method performed in the UNC Hospitals Molecular Genetics CLIA-  
184 certified laboratory. Copy number variant analysis was not conducted due to restrictions based  
185 on the study's Investigational Device Exemption approved by the FDA<sup>13</sup>.

186 For participants who decided to learn some or all of the additional findings categories,  
187 ES data were analyzed to identify P/LP variants in 22 genes associated with adult-onset  
188 actionable conditions, 234 genes associated with childhood-onset nonactionable conditions,  
189 and/or 871 genes associated with carrier findings for autosomal recessive conditions.

190 All parents were seen by a genetic counselor and/or clinical geneticist for return of any  
191 positive results in diagnostic, NGS-NBS, childhood-onset medically non-actionable and adult-  
192 onset medically actionable categories. Positive results for carrier status were conveyed by a  
193 genetic counselor only by phone. Recommendations and options for further testing or evaluation  
194 were provided but not part of the study. Parents were given a copy of the CLIA-confirmed result

195 report for their child and were given the option of having the results placed in their child's  
196 electronic health record.

197

198

## 199 **Results**

200 Molecular analysis was completed for 106 participants: 61 in the healthy/well-child  
201 cohort, 17 in the metabolic cohort and 28 in the hearing loss cohort. A total of 43 out of 46  
202 variants detected by ES were confirmed by orthogonal testing in the CLIA-certified laboratory  
203 prior to reporting. Additionally, 5 variants that were previously identified by clinical molecular  
204 testing were also detected by ES.

205

### 206 Metabolic cohort

207 NGS-NBS analysis was deemed to represent an abnormal, "positive screen" result in 15  
208 of 17 participants (88%) in the metabolic cohort (Tables 1 and 2). These individuals had a  
209 combination of pathogenic and/or likely pathogenic variants in genes implicated in metabolic  
210 conditions, that, when blinded to the participants' cohort, were determined to be reportable in a  
211 screening setting.

212 Seven participants previously diagnosed with phenylketonuria (PKU) by newborn  
213 screening had pathogenic variants in *PAH* (MIM: 612349); six of them were likely compound  
214 heterozygous for two different variants (ranging from missense, canonical splice-site, nonsense,  
215 and/or deletion variants). In view of their previously established diagnosis of PKU, we did not  
216 routinely perform parental testing to confirm the phase of these *PAH* variants. The seventh

217 participant was likely homozygous for a pathogenic missense variant in *PAH* (c.194T>C  
218 (p.I65T)), although we did not rule out the possibility of a deletion *in trans*.

219           Seven participants previously diagnosed with medium-chain acyl-coA dehydrogenase  
220 (MCAD) deficiency (MIM: 201450) by newborn screening had pathogenic variants in *ACADM*  
221 (MIM 607008); five of these seven were homozygous for a well-known pathogenic missense  
222 variant (c.985A>G (p.K329E)) reported previously in individuals with MCAD deficiency<sup>22–25</sup>. Two  
223 of these seven were likely compound heterozygous for two different variants in the *ACADM*  
224 gene: c.985A>G (p.K329E) and c.799G>A (p.G267R); c.985A>G (p.K329E) and c.199T>C  
225 (p.Y67H).

226           One participant who was previously diagnosed with carnitine deficiency (MIM: 212140)  
227 by newborn screening was homozygous for a pathogenic *SLC22A5* (MIM: 603377) missense  
228 variant (c.506G>A (p.R169Q)) consistent with his clinical diagnosis<sup>26–29</sup>.

229           NGS-NBS analysis was deemed “negative” in 2 of 17 participants (12%) in the metabolic  
230 cohort. However, after unblinding, diagnostic analysis revealed suggestive, but inconclusive  
231 findings (Tables 1 and 2). One participant previously diagnosed with maple syrup urine disease  
232 (MSUD, MIM: 248600) was heterozygous for a pathogenic missense variant in the *BCKDHA*  
233 (MIM: 608348) gene (c.1312T>A (p.Y438N)) associated with classic, autosomal recessive  
234 MSUD<sup>30–34</sup>. Since we did not identify any additional variants in *BCKDHA* that might explain a  
235 genetic etiology for this participant’s disease, we classified this result as inconclusive. Another  
236 participant previously diagnosed with malonyl-CoA decarboxylase deficiency (MIM: 248360)  
237 was homozygous for a missense variant (c.1013T>C (p.L338P)) in *MLYCD* (MIM: 606761), the  
238 gene that encodes the malonyl-CoA decarboxylase enzyme, but this variant was classified as a  
239 VUS due to insufficient evidence. Of note, this infant was born prematurely at 23 weeks  
240 gestation, and required several repeat newborn screens due to inconclusive findings prior to  
241 eventual confirmation of malonyl-CoA decarboxylase deficiency at 7 weeks of age.

242

243 Hearing loss cohort

244 NGS-NBS analysis was deemed to represent an abnormal, “positive screen” result in 5  
245 of 28 participants (18%) in the hearing loss cohort (Tables 1 and 3). These individuals had a  
246 combination of pathogenic and/or likely pathogenic variants in genes implicated in hearing loss  
247 that, when blinded to cohort, were determined to be reportable in a screening setting. Two  
248 participants were each presumed to be compound heterozygous for two variants in the *USH2A*  
249 (MIM: 608400) gene based on ES data (c.1256G>T (p.C419F) and c.3686T>G (p.L1229Ter);  
250 c.4338\_4339 delCT (p.C1447fs) and c.2299delG (p.E767fs)). In both cases, we subsequently  
251 confirmed that the variants were *in trans* by parental testing. One participant was homozygous  
252 for a 1-bp frameshift deletion (c.35delG (p.G12fs)) in *GJB2* (MIM: 121011; encoding connexin  
253 26), a common pathogenic variant associated with DFNB1 nonsyndromic deafness (MIM:  
254 220290)<sup>35–38</sup>. One participant was compound heterozygous for 2 pathogenic missense variants  
255 (c.626G>T (p.G209V) and c.1151A>G (p.E384G)) in *SLC26A4* (MIM: 605646), a gene  
256 associated with Pendred syndrome (MIM: 274600), an autosomal recessive form of syndromic  
257 hearing loss<sup>39–43</sup>. Finally, one participant was heterozygous for a pathogenic variant (c.5597C>T  
258 (p.T1866M)) in *TECTA* (MIM: 602574), a gene associated with autosomal dominant hearing  
259 loss (MIM: 601543)<sup>44–46</sup>. Of note, this infant passed her newborn hearing screen, but presented  
260 at one year of age with unilateral hearing loss that progressed to both ears. She was included in  
261 the study after referral by her audiologist, despite not fitting the original enrollment criteria, as  
262 her hearing loss was not detected by newborn screening.

263 In 5 of 28 participants in the hearing loss cohort, NGS-NBS screening analysis was  
264 deemed “negative.” However, after unblinding, diagnostic analysis identified 5 “inconclusive”  
265 results that may provide a possible explanation for their hearing loss (Tables 1 and 3). One  
266 participant was heterozygous for the pathogenic c.35delG (p.G12fs) deletion in *GJB2*. No

267 additional pathogenic variants were detected in *GJB2*, and analysis in the CLIA-certified  
268 laboratory for intragenic *GJB6* (MIM: 604418) deletions was negative; however, we cannot rule  
269 out the presence of a second pathogenic variant in *GJB2* not detected by ES, such as a partial  
270 gene deletion or cryptic splice alteration caused by a non-coding variant.

271 A few other “inconclusive” findings were reported that did not provide definitive  
272 diagnostic results. One participant was heterozygous for four different missense VUSs in genes  
273 associated with hearing loss: two variants in *LOXHD1* (MIM: 613072) (c.2914G>A (p.E972K)  
274 and c.3161C>T (p.T1054M)); one variant in *CEMIP*, also known as *KIAA1199* (MIM: 608366)  
275 (c.58C>T (p.L20F)) and one variant in *MYH14* (MIM: 608568) (c.5942G>C (p.G1981A)). One  
276 participant was heterozygous for a missense VUS in *SOX10* (MIM: 602229) (c.482G>A  
277 (p.R161H)); a gene associated with autosomal dominant Waardenburg syndrome (MIM: 611584,  
278 613266)<sup>47</sup>. One participant was homozygous for a missense VUS in *MYO7A* (MIM: 276903)  
279 (c.5824G>A (p.G1942R)); a gene associated with autosomal recessive syndromic and non-  
280 syndromic hearing loss (MIM: 276900, 600060)<sup>48,49</sup>. One participant was compound  
281 heterozygous for one likely pathogenic variant and one VUS in *TMPRSS3* (MIM: 605511):  
282 c.208delC (p.H70fs) and c.1151T>A (p.M384K); parental testing indicated that each variant was  
283 *in trans*.

284 We did not identify any P or LP variants on the diagnostic gene lists for 18 out of 28  
285 (64%) participants in the hearing loss cohort; therefore, diagnostic analyses were deemed  
286 negative for identifying a genetic cause of hearing loss in these individuals (Table 1).  
287 Interestingly, one participant referred by audiologists to the hearing loss cohort had a rare  
288 syndromic diagnosis, Warsaw breakage syndrome (MIM: 613398), which is characterized by  
289 severe microcephaly and intellectual disability, growth restriction and sensorineural hearing loss  
290 due to cochlear hypoplasia<sup>50,51</sup>. Clinical quad exome sequencing of the similarly affected sibling,  
291 this participant and parents revealed a homozygous pathogenic variant in exon 13 of the *DDX11*

292 (MIM: 601150) gene (c.1403dupT (p.S469fs)) in the participant and his sibling. This *DDX11*  
293 c.1403dupT (p.S469fs) variant was present in the NC NEXUS research ES data but was not  
294 examined because the *DDX11* gene was not included in either the NGS-NBS list or the hearing  
295 loss diagnostic list. If additional phenotypic information had been available at the time of  
296 molecular analysis, it is likely this variant would have been recognized as having diagnostic  
297 significance.

298

### 299 NGS-NBS conditions

300 An abnormal, “positive” NGS-NBS result was also defined as a finding that predicted a  
301 childhood-onset actionable condition in any individual in the well-child cohort, or a condition  
302 unrelated to the indicated diagnosis of a member of one of the affected cohorts. NGS-NBS  
303 analysis was deemed “positive” in 4 of 106 participants (Table 4). One participant in the well-  
304 child cohort was heterozygous for a missense *LDLR* (MIM: 606945) variant (c.502G>A  
305 (p.D168N)) previously reported in autosomal dominant familial hypercholesterolemia (MIM:  
306 143890)<sup>52–58</sup>. After disclosure of this finding, the parents stated that they were aware of a family  
307 history of hypercholesterolemia.

308 One female participant in the metabolic cohort, diagnosed with PKU, was a carrier of a  
309 missense variant (c.1061T>G (p.F354C)) in the ornithine transcarbamylase (*OTC*, MIM: 300461)  
310 gene. This variant was previously reported in mild *OTC* deficiency (MIM: 311250)<sup>59,60</sup>, an X-  
311 linked disease with variable expressivity in carrier females. Although this participant was  
312 diagnosed with PKU by the standard newborn screen at birth, the *OTC* deficiency was an  
313 unexpected finding arising from the ES analysis. Her ammonia levels are normal, and the  
314 variant was also found in her unaffected grandfather. Her younger male sibling was prenatally  
315 diagnosed with the variant, which enabled early measurement of ammonia level immediately

316 after delivery and appropriate ongoing health supervision. So far, he has been asymptomatic.  
317 One hearing loss cohort participant was heterozygous for a canonical splice-site variant in the  
318 *DSC2* (MIM: 125645) gene (c.631-2A>G (p.?)). This variant has been reported previously in  
319 individuals with autosomal dominant arrhythmogenic right ventricular dysplasia (MIM: 610476)<sup>61</sup>.  
320 This child has had a normal echo and it was recommended that the child be followed by a  
321 cardiologist. Another hearing loss cohort participant had two variants in the *F11* (MIM: 264900)  
322 gene (nonsense variant c.1489C>T (p.R497Ter) and missense variant c.1608G>C (p.K536N)).  
323 Both variants have been reported previously in individuals with autosomal recessive factor XI  
324 deficiency (MIM: 612416)<sup>62-64</sup>. This child has a history of frequent episodes of epistaxis  
325 (nosebleeds), one requiring cauterization. It was recommended that she be evaluated by a  
326 hematologist, and it was also recommended that precautions are taken prior to any surgical  
327 procedures.

328

### 329 Parental decision-making and additional genomic information

330 A total of 65 participants were randomized into the experimental decision arm of the  
331 study, viewed the decision aid, and attended the study visit with a genetic counselor. Over 90%  
332 of these parents chose to learn at least one category of additional genomic information: 47  
333 (72.3%) requested all three categories of additional information, 7 requested additional findings  
334 for both adult-onset actionable conditions and carrier status, 2 requested additional findings for  
335 the adult-onset actionable category only, 1 requested carrier status only, 1 requested findings  
336 for the adult-onset actionable and childhood-onset nonactionable conditions categories, and 1  
337 requested the childhood-onset nonactionable category only. The parents of 6 participants (9.2%)  
338 elected not to receive any of the additional information categories.

339 Two participants had additional findings in the adult-onset actionable category  
340 (Supplemental Table 2). A participant in the metabolic cohort was heterozygous for a  
341 pathogenic deletion *RAD51C* (MIM: 602774) variant (c.905-2\_905-1delAG (p.??)), which is  
342 predicted to alter a splice site and has been reported previously in autosomal dominant familial  
343 ovarian cancer (MIM: 613399)<sup>65,66</sup>. This participant had a known family history of breast cancer,  
344 but no known family history of ovarian cancer. A participant in the well-child cohort was  
345 heterozygous for a nonsense c.7480C>T (p.R2494Ter) variant in *BRCA2* (MIM: 600185) that is  
346 a known pathogenic variant associated with autosomal dominant familial breast and ovarian  
347 cancer (MIM: 612555)<sup>67-74</sup>. This participant's parents reported a maternal family history of breast  
348 and pancreatic cancer. The child's mother was referred to adult genetics.

349 One participant in the hearing loss cohort had an additional finding for the childhood-  
350 onset nonactionable conditions category (Supplemental Table 2). This participant was  
351 hemizygous for a likely pathogenic nonsense variant (c.741G>A (p.W247Ter)) in the *OCRL*  
352 (MIM: 300535) gene. This gene is associated with Lowe syndrome<sup>75</sup> (MIM: 309000), and further  
353 correlation with clinical findings indicated that the participant has multiple features consistent  
354 with Lowe syndrome. Indeed, we subsequently learned that the patient had been seen in clinical  
355 genetics and clinical exome sequencing was considered, but not performed due to concerns  
356 about cost. Although hearing loss is not a prominent feature of Lowe syndrome, there is at least  
357 one previous case report<sup>76</sup> involving an individual with Lowe syndrome who also had hearing  
358 loss, suggesting that the finding may provide a comprehensive diagnostic result for this  
359 participant's symptoms. The mother of this patient is a carrier of the variant and cascade testing  
360 of other family members has been negative.

361 The number of carrier findings in children whose parents requested this category ranged  
362 from 0-7 variants, with an average of 1.8 reportable carrier findings per individual (Figure 1,  
363 Supplemental Table 2). A total of 100 out of 109 (92%) potential carrier findings detected by ES

364 were confirmed by orthogonal testing in a CLIA-certified laboratory and reported. The nine  
365 variants that failed to be confirmed by orthogonal testing had low read depth for both alleles in  
366 the ES data. We observed several recurrent carrier findings; the most common were variants in  
367 the genes *HFE* (MIM: 613609), *GALT* (MIM:606999), *SERPINA1* (MIM:107400), and *RBM8A*  
368 (MIM: 605313) (Figure 2). A total of 11 participants carried the *HFE* c.187C>G (p.H63D) variant,  
369 while 4 carried the *HFE* c.845G>A (p.C282Y) variant, both associated with hereditary  
370 hemochromatosis (MIM: 235200)<sup>77,78</sup>. Four participants each carried the *SERPINA1* S or Z  
371 alleles (c.863A>T (p.E288V) and c.1096G>A (p.E366K)), respectively) associated with alpha-1-  
372 antitrypsin deficiency (MIM: 613490)<sup>79</sup>. Five participants were carriers for variants in *GALT* that  
373 are associated with the Duarte 2 allele<sup>80–82</sup> (including 1 missense variant and 3 intronic variants),  
374 while 2 participants were carriers for a variant associated with classic galactosemia (MIM:  
375 230400), c.563A>G (p.Q188R)<sup>83,84</sup>. Five participants carried a hypomorphic variant located in  
376 the 5' untranslated region (UTR) in *RBM8A* (c.-21G>A (p.?)), associated with  
377 thrombocytopenia-absent radius (TAR) syndrome (MIM: 274000)<sup>85,86</sup>. Additionally, we identified  
378 three carriers of pathogenic *CFTR* (MIM: 602421) variants associated with cystic fibrosis<sup>87–90</sup>  
379 (MIM: 219700); two participants carried the *CFTR* c.1521\_1523delCTT (p.F508del) founder  
380 variant and one participant carried the *CFTR* c.1519\_1521delATC (p.I507del) variant  
381 (Supplemental Table 2).

382

## 383 Discussion

384 The potential use of genome-scale sequencing to screen healthy individuals for  
385 monogenic disorders--before symptoms manifest--promises the tantalizing possibility of  
386 ameliorating these conditions, but also raises numerous challenges. Among the barriers to the  
387 use of genomic sequencing in any screening endeavor is the performance of this technology  
388 and our ability to interpret variants in the absence of phenotypic indications. Other critical issues

389 include the kinds of genomic information that should be offered, how parental informed consent  
390 can be obtained, and how the overall process and the potential results will impact families. To  
391 address these questions, the NC NEXUS study enrolled a cohort of 106 children: 17 with inborn  
392 errors of metabolism, 28 with hearing loss, and 61 healthy newborns. We explored the potential  
393 use of ES in the context of newborn screening, both from the standpoint of analytic performance  
394 as well as parental preferences for genomic information.

395

### 396 Analytic Performance

397 In order to assess how well ES would perform for predictive purposes, molecular  
398 analysts were initially blinded to the cohort status of the individual, enabling us to simulate the  
399 conditions of a true screening test, in which the individual is assumed to be at population risk.  
400 We did not perform trio analyses, which can be helpful for identifying *de novo* and compound  
401 heterozygous variants, although we did conduct follow-up parental sequencing whenever  
402 possible where compound heterozygosity was suspected. From the standpoint of  
403 implementation workflows, it is reasonable to attempt to obtain trio samples in order to maximize  
404 the diagnostic yield of clinical diagnostic sequencing; however, comprehensive trio sample  
405 collection would be impractical within current NBS practices.

406 Screening is unlike indication-based diagnostic testing, in which the analyst can utilize  
407 phenotypic information to judge which variants are most likely to be relevant, and where the  
408 disclosure of inconclusive results (variants of uncertain significance, single heterozygous  
409 variants in genes associated with recessive conditions, etc.) can still be informative and allow  
410 for more detailed clinical follow-up. However, in a population at low risk for any given monogenic  
411 disorder, disclosure of genomic findings with lower certainty will inevitably lead to an extremely  
412 high false positive rate, and we therefore set relatively stringent thresholds for the results to

413 qualify as a “positive screen.” This decision reflects the inevitable balance between increasing  
414 sensitivity to maximize case finding, versus establishing stringent thresholds to reduce false  
415 positives. As expected, a small number of participants (4 out of the total 106) had positive NGS-  
416 NBS screening results (beyond those that would be expected for those in the affected cohorts),  
417 but the results have implications for their health supervision. These findings exemplify the  
418 expansion of the possible range of conditions that could be identified in newborns, and thereby  
419 influence future health care and screening to ultimately improve clinical outcomes. These  
420 findings had implications for other family members, but longitudinal follow-up of a larger number  
421 of screened individuals will be required to assess outcomes, clinical utility, and the economic  
422 value of NGS-NBS. Among the affected cohorts, the screening analysis predicted the presence  
423 of inborn errors of metabolism in 15 out of 17 individuals and hearing loss in 5 out of 28  
424 individuals. Thus, at a population level, it is unlikely that genomic sequencing could replace  
425 current screening based on biochemical measurements or audiology testing.

426 In addition to a purely screening mode of analysis, genomic information could also be  
427 used in conjunction with phenotypic information (such as a metabolic screening assay or  
428 hearing screen) to perform a “secondary” or “indication-based” analysis. Therefore, after the  
429 analyst determined the “screening” results for a given individual, they were unblinded to the  
430 cohort that the individual was from, and a more sensitive diagnostic analysis was conducted.  
431 The yield of sequencing improved somewhat in the context of indication-based analysis: the two  
432 remaining individuals in the metabolic cohort and several members of the hearing loss cohort  
433 had highly suggestive, but “inconclusive” results (e.g. a single heterozygous pathogenic variant,  
434 a homozygous missense VUS in a gene associated with an autosomal recessive disease).  
435 These findings suggest that sequencing might be useful as an adjunct to traditional NBS  
436 methods, and that with improved detection of variants (such as non-canonical splicing variants,

437 copy number variants or rearrangements) and more extensive interpretive databases, the  
438 positive predictive value of genomic screening may improve.

439 A potential explanation for the relatively low diagnostic yield of ES for participants in the  
440 hearing loss cohort is that numerous factors<sup>91-95</sup> contribute to hearing loss, including non-  
441 genetic factors (i.e. environmental, infections, premature birth, etc.) that are estimated to  
442 account for approximately 20% of cases of prelingual hearing loss<sup>96</sup>. The diagnostic rate in our  
443 study likely reflects the genetic heterogeneity of the monogenic forms of hearing loss<sup>97,98</sup> as well  
444 as the incomplete knowledge of pathogenic variants. Ascertainment bias also may have led to a  
445 larger fraction of the hearing loss cohort having complex syndromic conditions that led the  
446 referring providers to consider exome sequencing as a useful diagnostic test. Other hearing loss  
447 patients may already have had panel testing, thus depleting the enrolled study population of the  
448 more commonly identified nonsyndromic hearing loss conditions. In addition, certain genetic  
449 forms of hearing loss are caused by copy number variants or mitochondrial DNA variants<sup>96,99</sup>,  
450 which were not assessed in this study. Due to the heterogeneity of the etiologies of hearing loss,  
451 it seems clear that phenotypic screening at birth will remain necessary, even if detection of the  
452 genetic mechanisms improves.

453 On the other hand, many types of hearing loss that would be detectable with genomic  
454 sequencing (for example, hearing loss due to pathogenic or likely pathogenic variants in *TECTA*  
455 as shown in one NC NEXUS patient) do not have congenital onset and would therefore be  
456 missed at birth. The pathogenic *TECTA* variant finding demonstrates the potential for NGS-NBS  
457 to detect hearing loss risk in children who are not identified through traditional newborn hearing  
458 screening. The identification of a genetic risk for hearing loss in this setting could be followed up  
459 with more aggressive audiology evaluations during infancy and early childhood in order to  
460 facilitate interventions and reduce the chance of language impairment. In other cases, hearing  
461 loss is associated with a broader syndromic condition, for example the NC NEXUS patients with

462 Warsaw Breakage Syndrome or Lowe Syndrome. These examples raise intriguing points  
463 regarding the implementation of genomic screening in newborns, where testing in the context of  
464 a specific phenotype can be a powerful diagnostic tool enabling families and clinicians to better  
465 manage an individual's health condition. However, it is unclear whether routine screening of all  
466 healthy newborns for such conditions would be useful in a broader context without clinical  
467 interventions to ameliorate symptoms; in such cases, parental input will be critical.

468

469

#### 470 Parental decision-making and additional genomic findings

471 One question raised by the prospect of genomic sequencing in newborns is how parents  
472 will be engaged in the process of informed decision making. After using an online decision aid  
473 and discussion with a genetic counselor, over 72% of parents in our study who were eligible to  
474 learn additional findings chose to learn information in all three categories. The carrier findings  
475 reported in this study were similar to other studies<sup>10,100-103</sup>. Interestingly, many of the variants we  
476 observed are milder or hypomorphic variants; in order to cause disease, these alleles must be *in*  
477 *trans* with a more severe variant in the same gene (e.g. the *RBM8A* c.-21G>A (p.?) variant and  
478 the *HFE* c.187C>G (p.H63D) variant). These hypomorphic variants complicate the analysis and  
479 the reporting of carrier findings. In addition, identifying carrier status in a newborn is not fully  
480 informative with regards to carrier status in the parents or siblings without further analysis, which  
481 decreases the clinical utility of reporting carrier findings in infants. Parental preferences  
482 identified in this study may have limited generalizability given that ~40% of the participants  
483 already had health conditions with a possible genetic etiology. Other factors may also have  
484 influenced whether parents decided to enroll their child to participate in the NC NEXUS study

485 (e.g. parents' education level, parents' general feelings about research studies). Much  
486 information remains to be learned about parental decisions in diverse contexts.

487

#### 488 Conclusions and future directions

489       Clinical applications of genomic sequencing technologies offer great opportunities in  
490 both diagnostic testing and screening. In the context of NBS, sequencing-based approaches  
491 cannot fully replace biochemical or phenotypic screens because of etiologic heterogeneity and  
492 the challenges of variant interpretation. However, sequencing approaches have the advantage  
493 of being able to identify virtually any condition with a known genetic cause. Thus, augmentation  
494 of newborn screening with some form of genomic sequencing seems inevitable. In the near term,  
495 sequencing of genes already associated with conditions that are screened for in traditional NBS  
496 may help to improve clinical sensitivity and specificity. Expanding the current NBS panel to  
497 include other actionable conditions detectable only by sequencing could further enhance the  
498 public health benefits of NBS, if interpretive challenges can be overcome in order to balance  
499 case detection versus false positives. Providing additional genomic information beyond the most  
500 actionable conditions, while potentially of interest to many parents, may increase the complexity  
501 of informed consent and thereby serve to distract from the primary health benefits of NGS-NBS.  
502 There will be significant costs, ethical considerations and implementation challenges involved in  
503 conducting genome-scale sequencing in healthy newborns. These challenges may limit broad  
504 application across the entire population, thus failing to deliver on the promise of the Human  
505 Genome Project. We should therefore continue to explore innovative approaches to NGS-NBS  
506 that will enable the most comprehensive adoption in the general population, improve outcomes  
507 to the greatest extent possible, and maximize societal benefits in a cost-effective manner.

#### 508 **Description of Supplemental Data**

509 Supplemental data include 2 tables.

## 510 **Declaration of Interests**

511 D.B.B. is involved in an unrelated research study that receives equipment and reagents from  
512 Asuragen. B.C.P. is an investigator on a different research study that receives in-kind support  
513 (reagents and sequencing consumables) from Illumina (San Diego, CA). K.E.W. is President  
514 and Chair of the Executive Committee and Board of Directors for the Association for Molecular  
515 Pathology, a member of the Advisory Committee for the U.S. F.D.A. Medical Devices Molecular  
516 and Clinical Genetics Devices Panel, and a member of the Consultant Advisory Panel for  
517 BlueCross BlueShield of North Carolina.

## 518 **Acknowledgments**

519 We thank the families who participated in the study. This work was funded by the National  
520 Human Genome Research Institute and the *Eunice Kennedy Shriver* National Institute of Child  
521 Health and Human Development of the National Institutes of Health as part of the Newborn  
522 Sequencing in Genomic Medicine and Public Health (NSIGHT) Program, U19 HD077632. We  
523 gratefully acknowledge the UNC BioSpecimen Processing Facility and the UNC High-  
524 Throughput Sequencing Facility for their work in DNA extraction, sample preparation and exome  
525 sequencing, and Manyu Li and the UNC Hospitals Clinical Molecular Genetics Laboratory. We  
526 also thank Jason Reilly, Ian Wilhelmsen, Kirk Wilhelmsen, Dylan Young and the Renaissance  
527 Computing Institute (RENCI) at UNC for bioinformatics analysis and expertise; Alexandra  
528 Arreola and Claire Edgerly for contributions to molecular analysis; and Lonna Mollison and  
529 Kathleen Wallace for their contributions to curating the NGS-NBS and additional findings gene  
530 lists.

531 ClinicalTrials.gov Identifier: NCT02826694

## 532 **Web Resources**

533 Online Mendelian Inheritance in Man: [Omim.org](http://omim.org)

534 ClinVar database: [ncbi.nlm.nih.gov/clinvar/](http://ncbi.nlm.nih.gov/clinvar/)

535 UCSC genome browser: [genome.ucsc.edu](http://genome.ucsc.edu)

536 Genome Aggregation Database: [gnomad.broadinstitute.org](http://gnomad.broadinstitute.org)

537 Exome Aggregation Consortium Browser: [exac.broadinstitute.org](http://exac.broadinstitute.org)

538 ClinGen Variant Pathogenicity Curation Interface: [curation.clinicalgenome.org](http://curation.clinicalgenome.org)

539 **References**

540 1. Guthrie, R., and Susi, A. (1963). A simple phenylalanine method for detecting  
541 phenylketonuria in large populations of newborn infants. *Pediatrics* *32*, 338–343.

542 2. Frazier, D.M., Millington, D.S., McCandless, S.E., Koeberl, D.D., Weavil, S.D., Chaing, S.H.,  
543 and Muenzer, J. (2006). The tandem mass spectrometry newborn screening experience in  
544 North Carolina: 1997-2005. *J. Inherit. Metab. Dis.* *29*, 76–85.

545 3. Centers for Disease Control and Prevention (CDC). (2008). Impact of expanded newborn  
546 screening--United States, 2006. *MMWR Morb Mortal Wkly Rep.* *57*, 1012–1015.

547 4. Hammett-Stabler, C.A., and Garg, U. (2010). *Clinical Applications of Mass Spectrometry*  
548 *Methods and Protocols* (Humana Press).

549 5. Watson, M.S., Mann, M.Y., Lloyd-Puryear, M.A., Rinaldo, P., Howell, R.R., Cordero, J.,  
550 Edwards, E.S., Howse, J.L., Mullaley, T., Van Dyck, P., et al. (2006). Newborn screening:  
551 Toward a uniform screening panel and system - Executive summary. *Pediatrics* *117*, S296-307.

552 6. Sweetman, L., Millington, D.S., Therrell, B.L., Hannon, W.H., Popovich, B., Watson, M.S.,  
553 Mann, M.Y., Lloyd-Puryear, M.A., and Van Dyck, P.C. (2006). Naming and counting disorders  
554 (conditions) included in newborn screening panels. *Pediatrics* *117*, S308-14.

- 555 7. Watson, M.S., Mann, M.Y., Lloyd-Puryear Michele A., Rinaldo, P., and Howell, R.R. (2006).  
556 Executive summary. *Genet. Med.* 8, 1S-11S.
- 557 8. Choi, M., Scholl, U.I., Ji, W., Liu, T., Tikhonova, I.R., Zumbo, P., Nayir, A., Bakkaloğlu, A.,  
558 Ozen, S. Sanjad, S., et al. (2009). Genetic diagnosis by whole exome capture and massively  
559 parallel DNA sequencing. *Proc. Natl. Acad. Sci. U. S. A.* 106, 19096–19101.
- 560 9. Berg, J.S., Agrawal, P.B., Bailey Jr., D.B., Beggs, A.H., Brenner, S.E., Brower, A.M., Cakici,  
561 J.A., Ceyhan-Birsoy, O., Chan, K., Chen, F., et al. (2017). Newborn sequencing in genomic  
562 medicine and public health. *Pediatrics* 139, e20162252.
- 563 10. Ceyhan-Birsoy, O., Murry, J.B., Machini, K., Lebo, M.S., Yu, T.W., Fayer, S., Genetti, C.A.,  
564 Schwartz, T.S., Agrawal, P.B., Parad, R.B., et al. (2019). Interpretation of genomic sequencing  
565 results in healthy and ill newborns: Results from the BabySeq project. *Am. J. Hum. Genet.* 104,  
566 76–93.
- 567 11. Kingsmore, S.F., Cakici, J.A., Clark, M.M., Gaughran, M., Feddock, M., Batalov, S.,  
568 Bainbridge, M.N., Carroll, J., Caylor, S.A., Clarke, C., et al. (2019). A randomized, controlled  
569 trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome  
570 sequencing in ill infants. *Am. J. Hum. Genet.* 105, 719–733.
- 571 12. Bassaganyas, L., Freedman, G., Vaka, D., Wan, E., Lao, R., Chen, F., Kvale, M., Currier,  
572 R.J., Puck, J.M., and Kwok, P.Y. (2018). Whole exome and whole genome sequencing with  
573 dried blood spot DNA without whole genome amplification. *Hum. Mutat.* 39, 167–171.
- 574 13. Milko, L. V., Rini, C., Lewis, M.A., Butterfield, R.M., Lin, F.C., Paquin, R.S., Powell, B.C.,  
575 Roche, M.I., Souris, K.J., Bailey, D.B., et al. (2018). Evaluating parents' decisions about next-  
576 generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome  
577 Sequencing for Universal Screening) study: A randomized controlled trial protocol. *Trials* 19,  
578 344.

- 579 14. Milko, L. V., O'Daniel, J.M., DeCristo, D.M., Crowley, S.B., Foreman, A.K.M., Wallace, K.E.,  
580 Mollison, L.F., Strande, N.T., Girnary, Z.S., Boshe, L.J., et al. (2019). An age-based framework  
581 for evaluating genome-scale sequencing results in newborn screening. *J. Pediatr.* *209*, 68–76.
- 582 15. Lewis, M.A., Paquin, R.S., Roche, M.I., Furberg, R.D., Rini, C., Berg, J.S., Powell, C.M., and  
583 Bailey, D.B. (2016). Supporting parental decisions about genomic sequencing for newborn  
584 screening: The NC NEXUS decision aid. *Pediatrics* *137*, S16–S23.
- 585 16. Lewis, M.A., Stine, A., Paquin, R.S., Mansfield, C., Wood, D., Rini, C., Roche, M.I., Powell,  
586 C.M., Berg, J.S., and Bailey, D.B. (2018). Parental preferences toward genomic sequencing for  
587 non-medically actionable conditions in children: A discrete-choice experiment. *Genet. Med.* *20*,  
588 181–189.
- 589 17. Paquin, R.S., Peinado, S., Lewis, M.A., Biesecker, B.B., Rini, C., Roche, M., Butterfield,  
590 R.M., Powell, C.M., Berg, J.S., and Bailey, D.B. (2018). A behavior-theoretic evaluation of  
591 values clarification on parental beliefs and intentions toward genomic sequencing for newborns.  
592 *Soc. Sci. Med.* 30651–30658.
- 593 18. Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B., Hart,  
594 J., Hoffman, D., Jang, W., et al. (2018). ClinVar: Improving access to variant interpretations and  
595 supporting evidence. *Nucleic Acids Res.* *46*, D1062–D1067.
- 596 19. Lek, M., Karczewski, K.J., Minikel, E. V., Samocha, K.E., Banks, E., Fennell, T., O'Donnell-  
597 Luria, A.H., Ware, J.S., Hill, A.J., Cummings, B.B., et al. (2016). Analysis of protein-coding  
598 genetic variation in 60,706 humans. *Nature* *536*, 285–291.
- 599 20. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,  
600 M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of  
601 sequence variants: A joint consensus recommendation of the American College of Medical  
602 Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* *17*, 405–424.

- 603 21. Oza, A.M., DiStefano, M.T., Hemphill, S.E., Cushman, B.J., Grant, A.R., Siegert, R.K., Shen,  
604 J., Chapin, A., Boczek, N.J., Schimmenti, L.A., et al. (2018). Expert specification of the  
605 ACMG/AMP variant interpretation guidelines for genetic hearing loss. *Hum. Mutat.* 39, 1593–  
606 1613.
- 607 22. Maier, E.M., Liebl, B., Röschinger, W., Nennstiel-Ratzel, U., Fingerhut, R., Olgemöller, B.,  
608 Busch, U., Krone, N., Kries, R. V., and Roscher, A.A. (2005). Population spectrum of *ACADM*  
609 genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-  
610 CoA dehydrogenase deficiency. *Hum. Mutat.* 25, 443–452.
- 611 23. Gregersen, N., Andresen, B.S., Bross, P., Winter, V., Rüdiger, N., Engst, S., Christensen, E.,  
612 Kelly, D., Strauss, A.W., Kølvråa, S., et al. (1991). Molecular characterization of medium-chain  
613 acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the  
614 *MCAD* gene, and expression of inactive mutant enzyme protein in *E. coli*. *Hum. Genet.* 86, 545–  
615 551.
- 616 24. Andresen, B.S., Dobrowolski, S.F., O’ Reilly, L., Muenzer, J., McCandless, S.E., Frazier,  
617 D.M., Udvari, S., Bross, P., Knudsen, I., Banas, R., et al. (2001). Medium-chain acyl-CoA  
618 dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of  
619 newborns differ from those observed in patients with clinical symptoms: Identification and  
620 characterization of a new, prevalent mutation that results in mild MCAD deficiency. *Am. J. Hum.*  
621 *Genet.* 68, 1408–1418.
- 622 25. Yokota, I., Coates, P.M., Hale, D.E., Rinaldo, P., and Tanaka, K. (1991). Molecular survey of  
623 a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the  
624 medium-chain acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. *Am.*  
625 *J. Hum. Genet.* 49, 1280–1291.
- 626 26. Yoon, Y.A., Lee, D.H., Ki, C.S., Lee, S.Y., Kim, J.W., Lee, Y.W., and Park, H.D. (2012).

- 627 *SLC22A5* mutations in a patient with systemic primary carnitine deficiency: The first Korean  
628 case confirmed by biochemical and molecular investigation. *Ann. Clin. Lab. Sci.* **42**, 424–428.
- 629 27. Li, F.Y., El-Hattab, A.W., Bawle, E. V., Boles, R.G., Schmitt, E.S., Scaglia, F., and Wong,  
630 L.J. (2010). Molecular spectrum of *SLC22A5* (OCTN2) gene mutations detected in 143 subjects  
631 evaluated for systemic carnitine deficiency. *Hum. Mutat.* **31**, E1632-51.
- 632 28. Burwinkel, B., Kreuder, J., Schweitzer, S., Vorgerd, M., Gempel, K., Gerbitz, K.D., and  
633 Kilimann, M.W. (1999). Carnitine transporter OCTN2 mutations in systemic primary carnitine  
634 deficiency: A novel Arg169Gln mutation and a recurrent arg282ter mutation associated with an  
635 unconventional splicing abnormality. *Biochem. Biophys. Res. Commun.* **261**, 484–487.
- 636 29. Rose, E.C., di San Filippo, C.A., Ndukwe Erlingsson, U.C., Ardon, O., Pasquali, M., and  
637 Longo, N. (2012). Genotype-phenotype correlation in primary carnitine deficiency. *Hum. Mutat.*  
638 **33**, 118–123.
- 639 30. Love-Gregory, L.D., Grasela, J., Hillman, R.E., and Phillips, C.L. (2002). Evidence of  
640 common ancestry for the maple syrup urine disease (MSUD) Y438N allele in non-Mennonite  
641 MSUD patients. *Mol. Genet. Metab.* **75**, 79–90.
- 642 31. Zhang, B., Edenberg, H.J., Crabb, D.W., and Harris, R.A. (1989). Evidence for both a  
643 regulatory mutation and a structural mutation in a family with maple syrup urine disease. *J. Clin.*  
644 *Invest.* **83**, 1425–1429.
- 645 32. Matsuda, I., Nobukuni, Y., Mitsubuchi, H., Indo, Y., Endo, F., Asaka, J., and Harada, A.  
646 (1990). A T-to-A substitution in the E1 $\alpha$  subunit gene of the branched-chain  $\alpha$ -ketoacid  
647 dehydrogenase complex in two cell lines derived from menonite maple syrup urine disease  
648 patients. *Biochem. Biophys. Res. Commun.* **172**, 646–651.
- 649 33. Fisher, C.R., Chuang, J.L., Cox, R.P., Fisher, C.W., Star, R.A., and Chuang, D.T. (1991).

650 Maple syrup urine disease in mennonites. Evidence that the Y393N mutation in E1 $\alpha$  impedes  
651 assembly of the E1 component of branched-chain  $\alpha$ -keto acid dehydrogenase complex. *J. Clin.*  
652 *Invest.* *88*, 1034–1037.

653 34. Stojiljkovic, M., Klaassen, K., Djordjevic, M., Sarajlija, A., Brasil, S., Kecman, B., Grkovic, S.,  
654 Kostic, J., Rodriguez-Pombo, P., Desviat, L.R., et al. (2016). Molecular and phenotypic  
655 characteristics of seven novel mutations causing branched-chain organic acidurias. *Clin. Genet.*  
656 *90*, 252–257.

657 35. D'Andrea, P., Veronesi, V., Bicego, M., Melchionda, S., Zelante, L., Di Iorio, E., Bruzzone,  
658 R., and Gasparini, P. (2002). Hearing loss: Frequency and functional studies of the most  
659 common connexin26 alleles. *Biochem. Biophys. Res. Commun.* *296*, 685–691.

660 36. Zelante, L., Gasparini, P., Estivill, X., Melchionda, S., D'Agruma, L., Govea, N., Milá, M.,  
661 Della Monica, M., Lutfi, J., Shohat, M., et al. (1997). Connexin26 mutations associated with the  
662 most common form of non-syndromic neurosensory autosomal recessive deafness (DFNB1) in  
663 Mediterraneans. *Hum. Mol. Genet.* *6*, 1605–1609.

664 37. Carrasquillo, M.M., Zlotogora, J., Barges, S., and Chakravarti, A. (1997). Two different  
665 connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness:  
666 Implications for genetic studies in isolated populations. *Hum. Mol. Genet.* *6*, 2163–2172.

667 38. Morell, R.J., Kim, H.J., Hood, L.J., Goforth, L., Friderici, K., Fisher, R., Van Camp, G., Berlin,  
668 C.I., Oddoux, C., Ostrer, H., et al. (1998). Mutations in the connexin 26 gene (*GJB2*) among  
669 Ashkenazi jews with nonsyndromic recessive deafness. *N. Engl. J. Med.* *339*, 1500–1505.

670 39. Chattaraj, P., Munjal, T., Honda, K., Rendtorff, N.D., Ratay, J.S., Muskett, J.A., Risso, D.S.,  
671 Roux, I., Gertz, E.M., Schäffer, A.A., et al. (2017). A common *SLC26A4*-linked haplotype  
672 underlying non-syndromic hearing loss with enlargement of the vestibular aqueduct. *J. Med.*  
673 *Genet.* *54*, 665–673.

- 674 40. Scott, D.A. (2000). Functional differences of the *PDS* gene product are associated with  
675 phenotypic variation in patients with Pendred syndrome and non-syndromic hearing loss  
676 (DFNB4). *Hum. Mol. Genet.* 9, 1709–1715.
- 677 41. Choi, B.Y., Stewart, A.K., Madeo, A.C., Pryor, S.P., Lenhard, S., Kittles, R., Eisenman, D.,  
678 Kim, H.J., Niparko, J., Thomsen, J., et al. (2009). Hypo-functional *SLC26A4* variants associated  
679 with nonsyndromic hearing loss and enlargement of the vestibular aqueduct: genotype-  
680 phenotype correlation or coincidental polymorphisms? *Hum. Mutat.* 30, 599–608.
- 681 42. Coyle, B., Reardon, W., Herbrick, J.A., Tsui, L.C., Gausden, E., Lee, J., Coffey, R., Grueters,  
682 A., Grossman, A., Phelps, P.D., et al. (1998). Molecular analysis of the *PDS* gene in Pendred  
683 syndrome (sensorineural hearing loss and goitre). *Hum. Mol. Genet.* 7, 1105–1112.
- 684 43. Van Hauwe, P., Everett, L.A., Coucke, P., Scott, D.A., Kraft, M.L., Ris-Stalpers, C., Bolder,  
685 C., Otten, B., De Vijlder, J.J.M., Dietrich, N.L., et al. (1998). Two frequent missense mutations in  
686 Pendred syndrome. *Hum. Mol. Genet.* 7, 1099–1104.
- 687 44. Hildebrand, M.S., Morín, M., Meyer, N.C., Mayo, F., Modamio-Hoybjor, S., Mencía, A.,  
688 Olavarrieta, L., Morales-Angulo, C., Nishimura, C.J., Workman, H., et al. (2011). DFNA8/12  
689 caused by *TECTA* mutations is the most identified subtype of nonsyndromic autosomal  
690 dominant hearing loss. *Hum. Mutat.* 32, 825–834.
- 691 45. Sagong, B., Park, R., Kim, Y.H., Lee, K.Y., Baek, J.I., Cho, H.J., Cho, I.J., Kim, U.K., and  
692 Lee, S.H. (2010). Two novel missense mutations in the *TECTA* gene in Korean families with  
693 autosomal dominant nonsyndromic hearing loss. *Ann. Clin. Lab. Sci.* 40, 380–385.
- 694 46. Moteki, H., Nishio, S.Y., Hashimoto, S., Takumi, Y., Iwasaki, S., Takeichi, N., Fukuda, S.,  
695 and Usami, S.I. (2012). *TECTA* mutations in Japanese with mid-frequency hearing loss affected  
696 by zona pellucida domain protein secretion. *J. Hum. Genet.* 57, 587–592.

- 697 47. Chaoui, A., Watanabe, Y., Touraine, R., Baral, V., Goossens, M., Pingault, V., and  
698 Bondurand, N. (2011). Identification and functional analysis of *SOX10* missense mutations in  
699 different subtypes of Waardenburg syndrome. *Hum. Mutat.* *32*, 1436–1449.
- 700 48. Duman, D., Sirmaci, A., Cengiz, F.B., Ozdag, H., and Tekin, M. (2011). Screening of 38  
701 genes identifies mutations in 62% of families with nonsyndromic deafness in Turkey. *Genet.*  
702 *Test. Mol. Biomarkers* *15*, 29–33.
- 703 49. Bonnet, C., Riahi, Z., Chantot-Bastaraud, S., Smagghe, L., Letexier, M., Marcaillou, C.,  
704 Lefèvre, G.M., Hardelin, J.P., El-Amraoui, A., Singh-Estivalet, A., et al. (2016). An innovative  
705 strategy for the molecular diagnosis of Usher syndrome identifies causal biallelic mutations in 93%  
706 of European patients. *Eur. J. Hum. Genet.* *24*, 1730–1738.
- 707 50. van der Lelij, P., Chrzanowska, K.H., Godthelp, B.C., Rooimans, M.A., Oostra, A.B., Stumm,  
708 M., Zdzienicka, M.Z., Joenje, H., and de Winter, J.P. (2010). Warsaw breakage syndrome, a  
709 cohesinopathy associated with mutations in the XPD helicase family member *DDX11/ChIR1*.  
710 *Am. J. Hum. Genet.* *86*, 262–266.
- 711 51. Alkhunaizi, E., Brosh Jr., R.M., Alkuraya, F.S., and Chitayat, D. (2019). Warsaw Syndrome.  
712 GeneReviews, <http://ncbi.nlm.nih.gov/books/NBK541972/>.
- 713 52. Day, I.N.M., Whittall, R.A., O'Dell, S.D., Haddad, L., Bolla, M.K., Gudnason, V., and  
714 Humphries, S.E. (1997). Spectrum of LDL receptor gene mutations in heterozygous familial  
715 hypercholesterolemia. *Hum. Mutat.* *10*, 116–127.
- 716 53. Lee, W.K., Haddad, L., Macleod, M.J., Dorrance, A.M., Wilson, D.J., Gaffney, D.,  
717 Dominiczak, M.H., Packard, C.J.D., Day, I.N.M., Humphries, S.E., et al. (1998). Identification of  
718 a common low density lipoprotein receptor mutation (C163Y) in the west of Scotland. *J. Med.*  
719 *Genet.* *35*, 573–578.

- 720 54. Villéger, L., Abifadel, M., Allard, D., Rabès, J.P., Thiart, R., Kotze, M.J., Bérout, C., Junien,  
721 C., Boileau, C., and Varret, M. (2002). The UMD-LDLR database: Additions to the software and  
722 490 new entries to the database. *Hum. Mutat.* 20, 81–87.
- 723 55. Laurie, A.D., Scott, R.S., and George, P.M. (2004). Genetic screening of patients with  
724 familial hypercholesterolaemia (FH): A New Zealand perspective. *Atheroscler. Suppl.* 5, 13–15.
- 725 56. Etxebarria, A., Benito-Vicente, A., Stef, M., Ostolaza, H., Palacios, L., and Martin, C. (2015).  
726 Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats.  
727 *Atherosclerosis* 238, 304–312.
- 728 57. Thormaehlen, A.S., Schuberth, C., Won, H.H., Blattmann, P., Joggerst-Thomalla, B., Theiss,  
729 S., Asselta, R., Duga, S., Merlini, P.A., Ardissino, D., et al. (2015). Systematic cell-based  
730 phenotyping of missense alleles empowers rare variant association studies: A case for LDLR  
731 and myocardial infarction. *PLoS Genet.* 11, e1004855.
- 732 58. Civeira, F., Jarauta, E., Cenarro, A., García-Otín, A.L., Tejedor, D., Zambón, D., Mallen, M.,  
733 Ros, E., and Pocoví, M. (2008). Frequency of low-density lipoprotein receptor gene mutations in  
734 patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. *J. Am.*  
735 *Coll. Cardiol.* 52, 1546–1553.
- 736 59. Myers, J.H., and Shook, J.E. (1996). Vomiting, ataxia, and altered mental status in an  
737 adolescent: Late-onset ornithine transcarbamylase deficiency. *Am. J. Emerg. Med.* 14, 553–557.
- 738 60. Yamaguchi, S., Brailey, L.L., Morizono, H., Bale, A.E., and Tuchman, M. (2006). Mutations  
739 and polymorphisms in the human ornithine transcarbamylase (*OTC*) gene. *Hum. Mutat.* 27,  
740 626–632.
- 741 61. Heuser, A., Plovie, E.R., Ellinor, P.T., Grossmann, K.S., Shin, J.T., Wichter, T., Basson,  
742 C.T., Lerman, B.B., Sasse-Klaassen, S., Thierfelder, L., et al. (2006). Mutant desmocollin-2

- 743 causes arrhythmogenic right ventricular cardiomyopathy. *Am. J. Hum. Genet.* 79, 1081–1088.
- 744 62. Mitchell, M., Mountford, R., Butler, R., Alhaq, A., Dai, L., Savidge, G., and Bolton-Maggs,  
745 P.H.B. (2006). Spectrum of factor XI (*F11*) mutations in the UK population--116 index cases and  
746 140 mutations. *Hum. Mutat.* 27, 829.
- 747 63. Pike, G.N., Cumming, A.M., Hay, C.R.M., Sempasa, B., Sutherland, M., Thachil, J., Burthem,  
748 J., and Bolton-Maggs, P.H.B. (2016). In vitro comparison of the effect of two factor XI (FXI)  
749 concentrates on thrombin generation in major FXI deficiency. *Haemophilia* 22, 403–410.
- 750 64. Esteban, J., de la Morena-Barrio, M.E., Salloum-Asfar, S., Padilla, J., Miñano, A., Roldán, V.,  
751 Soria, J.M., Vidal, F., Corral, J., and Vicente, V. (2017). High incidence of FXI deficiency in a  
752 Spanish town caused by 11 different mutations and the first duplication of *F11*: Results from the  
753 Yecla study. *Haemophilia* 23, e488–e496.
- 754 65. Lhota, F., Zemankova, P., Kleiblova, P., Soukupova, J., Vocka, M., Stranecky, V., Janatova,  
755 M., Hartmannova, H., Hodanova, K., Kmoch, S., et al. (2016). Hereditary truncating mutations of  
756 DNA repair and other genes in *BRCA1/BRCA2/PALB2*-negatively tested breast cancer patients.  
757 *Clin. Genet.* 90, 324–333.
- 758 66. Song, H., Dicks, E., Ramus, S.J., Tyrer, J.P., Intermaggio, M.P., Hayward, J., Edlund, C.K.,  
759 Conti, D., Harrington, P., Fraser, L., et al. (2015). Contribution of germline mutations in the  
760 *RAD51B*, *RAD51C*, and *RAD51D* genes to ovarian cancer in the population. *J. Clin. Oncol.* 33,  
761 2901–2907.
- 762 67. Syrjäkoski, K., Kuukasjärvi, T., Waltering, K., Haraldsson, K., Auvinen, A., Borg, Å., Kainu,  
763 T., Kallioniemi, O.P., and Koivisto, P.A. (2004). *BRCA2* mutations in 154 Finnish male breast  
764 cancer patients. *Neoplasia* 6, 541–545.
- 765 68. Kim, H., Cho, D.Y., Choi, D.H., Choi, S.Y., Shin, I., Park, W., Huh, S.J., Han, S.H., Lee,

- 766 M.H., Ahn, S.H., et al. (2012). Characteristics and spectrum of *BRCA1* and *BRCA2* mutations in  
767 3,922 Korean patients with breast and ovarian cancer. *Breast Cancer Res. Treat.* *134*, 1315–  
768 1326.
- 769 69. Sun, J., Meng, H., Yao, L., Lv, M., Bai, J., Zhang, J., Wang, L., Ouyang, T., Li, J., Wang, T.,  
770 et al. (2017). Germline mutations in cancer susceptibility genes in a large series of unselected  
771 breast cancer patients. *Clin. Cancer Res.* *23*, 6113–6119.
- 772 70. Lim, M.C., Kang, S., Seo, S.S., Kong, S.Y., Lee, B.Y., Lee, S.K., and Park, S.Y. (2009).  
773 *BRCA1* and *BRCA2* germline mutations in Korean ovarian cancer patients. *J. Cancer Res. Clin.*  
774 *Oncol.* *135*, 1593–1599.
- 775 71. Han, S.H., Lee, K.R., Lee, D.G., Kim, B.Y., Lee, K.E., and Chung, W.S. (2006). Mutation  
776 analysis of *BRCA1* and *BRCA2* from 793 Korean patients with sporadic breast cancer. *Clin.*  
777 *Genet.* *70*, 496–501.
- 778 72. Ahn, S.H., Son, B.H., Yoon, K.S., Noh, D.Y., Han, W., Kim, S.W., Lee, E.S., Park, H.L.,  
779 Hong, Y.J., Choi, J.J., et al. (2007). *BRCA1* and *BRCA2* germline mutations in Korean breast  
780 cancer patients at high risk of carrying mutations. *Cancer Lett.* *245*, 90–95.
- 781 73. Seong, M., Cho, S.I., Noh, D., Han, W., Kim, S., Park, C., Park, H., Kim, S.Y., Kim, J.Y., and  
782 Park, S.S. (2009). Comprehensive mutational analysis of *BRCA1/BRCA2* for Korean breast  
783 cancer patients: Evidence of a founder mutation. *Clin. Genet.* *76*, 152–160.
- 784 74. Choi, D.H., Lee, M.H., Bale, A.E., Carter, D., and Haffty, B.G. (2004). Incidence of *BRCA1*  
785 and *BRCA2* mutations in young Korean breast cancer patients. *J. Clin. Oncol.* *22*, 1638–1645.
- 786 75. Hichri, H., Rendu, J., Monnier, N., Coutton, C., Dorseuil, O., Poussou, R.V., Baujat, G.,  
787 Blanchard, A., Nobili, F., Ranchin, B., et al. (2011). From Lowe syndrome to Dent disease:  
788 Correlations between mutations of the *OCRL1* gene and clinical and biochemical phenotypes.

- 789 Hum. Mutat. 32, 379–388.
- 790 76. Kim, H.K., Kim, J.H., Kim, Y.M., Kim, G.H., Lee, B.H., Choi, J.H., and Yoo, H.W. (2014).  
791 Lowe syndrome: a single center's experience in Korea. Korean J. Pediatr. 57, 140-8.
- 792 77. Barton, J.C., and Edwards, C.Q. (2018). *HFE* hemochromatosis. GeneReviews,  
793 <http://ncbi.nlm.nih.gov/books/NBK1440/>.
- 794 78. Pedersen, P., and Milman, N. (2009). Genetic screening for *HFE* hemochromatosis in 6,020  
795 Danish men: Penetrance of C282Y, H63D, and S65C variants. Ann. Hematol. 88, 775–784.
- 796 79. Stoller, J.K., Lacbawan, F.L., and Aboussouan, L.S. (2017). Alpha-1 antitrypsin deficiency.  
797 GeneReviews, <http://ncbi.nlm.nih.gov/books/NBK1519/>.
- 798 80. Carney, A.E., Sanders, R.D., Garza, K.R., McGaha, L.A., Bean, L.J.H., Coffee, B.W.,  
799 Thomas, J.W., Cutler, D.J., Kurtkaya, N.L., and Fridovich-Keil, J.L. (2009). Origins, distribution  
800 and expression of the Duarte-2 (D2) allele of galactose-1-phosphate uridylyltransferase. Hum.  
801 Mol. Genet. 18, 1624–1632.
- 802 81. Kozák, L., Francová, H., Pijácková, A., Macku, J., Stastná, S., Peskovová, K., Martincová,  
803 O., and Krijt, J. (1999). Presence of a deletion in the 5' upstream region of the *GALT* gene in  
804 Duarte (D2) alleles. J. Med. Genet. 36, 576–578.
- 805 82. Pyhtila, B.M., Shaw, K.A., Neumann, S.E., and Fridovich-Keil, J.L. (2015). Newborn  
806 screening for galactosemia in the United States: looking back, looking around, and looking  
807 ahead. JIMD Rep. 15, 79–93.
- 808 83. Fridovich-Keil, J.L., Langley, S.D., Mazur, L.A., Lennon, J.C., Dembure, P.P., and Elsas, L.J.  
809 (1995). Identification and functional analysis of three distinct mutations in the human galactose-  
810 1-phosphate uridylyltransferase gene associated with galactosemia in a single family. Am. J. Hum.  
811 Genet. 56, 640–646.

- 812 84. Reichardt, J.K.V., Packman, S., and Woo, S.L.C. (1991). Molecular characterization of two  
813 galactosemia mutations: Correlation of mutations with highly conserved domains in galactose-1-  
814 phosphate uridyl transferase. *Am. J. Hum. Genet.* *49*, 860–867.
- 815 85. Albers, C.A., Paul, D.S., Schulze, H., Freson, K., Stephens, J.C., Smethurst, P.A., Jolley,  
816 J.D., Cvejic, A., Kostadima, M., Bertone, P., et al. (2012). Compound inheritance of a low-  
817 frequency regulatory SNP and a rare null mutation in exon-junction complex subunit *RBM8A*  
818 causes TAR syndrome. *Nat. Genet.* *44*, 435–439.
- 819 86. Bottillo, I., Castori, M., De Bernardo, C., Fabbri, R., Grammatico, B., Preziosi, N., Scassellati,  
820 G.S., Silvestri, E., Spagnuolo, A., Laino, L., et al. (2013). Prenatal diagnosis and post-mortem  
821 examination in a fetus with thrombocytopenia-absent radius (TAR) syndrome due to compound  
822 heterozygosity for a 1q21.1 microdeletion and a *RBM8A* hypomorphic allele: A case report.  
823 *BMC Res. Notes.* *6*, 376.
- 824 87. Kerem, E., Corey, M., Kerem, B.S., Rommens, J., Markiewicz, D., Levison, H., Tsui, L.C.,  
825 and Durie, P. (1990). The relation between genotype and phenotype in cystic fibrosis-analysis of  
826 the most common mutation ( $\Delta F508$ ). *N. Engl. J. Med.* *323*, 1517–1522.
- 827 88. Kerem, B.S., Zielenski, J., Markiewicz, D., Bozon, D., Gazit, E., Yahav, J., Kennedy, D.,  
828 Riordan, J.R., Collins, F.S., Kommens, J.M., et al. (1990). Identification of mutations in regions  
829 corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. *Proc.*  
830 *Natl. Acad. Sci. U. S. A.* *87*, 8447–8451.
- 831 89. Nelson, P. V, Carey, W.F., and Morris, C.P. (1991). Identification of a cystic fibrosis mutation:  
832 deletion of isoleucine506. *Hum. Genet.* *86*, 391–393.
- 833 90. Orozco, L., Friedman, K., Chávez, M., Lezana, J.L., Villarreal, M.T., and Carnevale, A.  
834 (1994). Identification of the I507 deletion by site-directed mutagenesis. *Am. J. Med. Genet.* *51*,  
835 137–139.

- 836 91. Sundstrom, R.A., Van Laer, L., Van Camp, G., and Smith, R.J.H. (1999). Autosomal  
837 recessive nonsyndromic hearing loss. *Am. J. Med. Genet. - Semin. Med. Genet.* 89, 123–129.
- 838 92. Rehm, H.L., and Morton, C.C. (1999). A new age in the genetics of deafness. *Genet. Med.* 1,  
839 295–302.
- 840 93. Petit, C., Levilliers, J., and Hardelin, J.P. (2001). Molecular genetics of hearing loss. *Annu.*  
841 *Rev. Genet.* 35, 589–645.
- 842 94. Petersen, M. (2002). Non-syndromic autosomal-dominant deafness. *Clin Genet* 62, 1–13.
- 843 95. Korver, A.M.H., Smith, R.J.H., Van Camp, G., Schleiss, M.R., Bitner-Glindzicz, M.A.K.,  
844 Lustig, L.R., Usami, S.I., and Boudewyns, A.N. (2017). Congenital hearing loss. *Nat. Rev. Dis.*  
845 *Prim.* 3, 16094.
- 846 96. Shearer, A.E., Hildebrand, M.S., and Smith, R.J.H. (2017). Hereditary hearing loss and  
847 deafness overview. GeneReviews, <http://ncbi.nlm.nih.gov/books/NBK1434/>.
- 848 97. Alford, R.L., Arnos, K.S., Fox, M., Lin, J.W., Palmer, C.G., Pandya, A., Rehm, H.L., Robin,  
849 N.H., Scott, D.A., and Yoshinaga-Itano, C. (2014). American college of medical genetics and  
850 genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss. *Genet.*  
851 *Med.* 16, 347–355.
- 852 98. DiStefano, M.T., Hemphill, S.E., Oza, A.M., Siegert, R.K., Grant, A.R., Hughes, M.Y.,  
853 Cushman, B.J., Azaiez, H., Booth, K.T., Chapin, A., et al. (2019). ClinGen expert clinical validity  
854 curation of 164 hearing loss gene–disease pairs. *Genet. Med.* 21, 2239–2247.
- 855 99. Shearer, A.E., Kolbe, D.L., Azaiez, H., Sloan, C.M., Frees, K.L., Weaver, A.E., Clark, E.T.,  
856 Nishimura, C.J., Black-Ziegelbein, E.A., and Smith, R.J.H. (2014). Copy number variants are a  
857 common cause of non-syndromic hearing loss. *Genome Med.* 6, 37.
- 858 100. Punj, S., Akkari, Y., Huang, J., Yang, F., Creason, A., Pak, C., Potter, A., Dorschner, M.O.,

859 Nickerson, D.A., Robertson, P.D., et al. (2018). Preconception carrier screening by genome  
860 sequencing: Results from the clinical laboratory. *Am. J. Hum. Genet.* *102*, 1078–1089.  
861 101. Porter, K.M., Kauffman, T.L., Koenig, B.A., Lewis, K.L., Rehm, H.L., Richards, C.S.,  
862 Strande, N.T., Tabor, H.K., Wolf, S.M., Yang, Y., et al. (2018). Approaches to carrier testing and  
863 results disclosure in translational genomics research: The clinical sequencing exploratory  
864 research consortium experience. *Mol. Genet. Genomic Med.* *6*, 898–909.  
865 102. Umstead, K.L., Han, P.K.J., Lewis, K.L., Miller, I.M., Hepler, C.L., Thompson, L.J.,  
866 Wolfsberg, T.G., Nguyen, A.D., Fredriksen, M.T., Gibney, G., et al. (2019). Perceptions of  
867 uncertainties about carrier results identified by exome sequencing in a randomized controlled  
868 trial. *Transl. Behav. Med.* pii: ibz111.  
869 103. Machini, K., Ceyhan-Birsoy, O., Azzariti, D.R., Sharma, H., Rossetti, P., Mahanta, L.,  
870 Hutchinson, L., McLaughlin, H., MedSeq Project, Green, R.C., et al. (2019). Analyzing and  
871 reanalyzing the genome: Findings from the MedSeq project. *Am. J. Hum. Genet.* *105*, 177–188.

872

873 **Figure 1. Number of carrier findings for NC NEXUS participants that were randomized**  
874 **into the experimental group and elected to receive carrier findings**

875 Number of carrier findings is represented on the x-axis and the number of NC NEXUS  
876 participants is represented on the y-axis.

877

878 **Figure 2. Variants in *HFE*, *SERPINA1*, *GALT* and *RBM8A* were the most frequently**  
879 **observed carrier findings**

880 Variants/predicted protein changes and genes in which they are located are represented on the  
881 x-axis. Total number of carrier findings in the NC NEXUS study is represented on the y-axis.

882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894

<b>NC NEXUS cohort</b>	<b>Total number of participants in cohort</b>	<b>NGS-NBS positive</b>	<b>NGS-NBS Negative</b>	<b>Diagnostic positive</b>	<b>Diagnostic inconclusive</b>	<b>Diagnostic negative</b>
<b>Metabolic</b>	17	15	2	15	2	0
<b>Hearing Loss</b>	28	7*	21	5	5	18
<b>Healthy/Well-Child</b>	61	1*	60	0	0	0
	<b>Sum</b>					
<b>Unanticipated findings</b>	106	4	N/A	N/A	N/A	N/A

895 **Table 1: Summary of NGS-NBS and diagnostic findings in the NC NEXUS study**  
896 NGS-NBS positive indicates an abnormal, “positive screen,” defined by observing likely  
897 pathogenic and/or pathogenic variants in 466 genes associated with pediatric conditions with  
898 high medical actionability. NGS-NBS negative indicates a “negative screen,” defined by the  
899 absence of likely pathogenic or pathogenic variants found in these genes. Diagnostic positive  
900 indicates the presence of likely pathogenic or pathogenic variants found in gene(s) on the  
901 metabolic or hearing loss diagnostic list that are consistent with the participant’s disorder.

902 Diagnostic inconclusive indicates an inconclusive result, which was defined as a single  
 903 heterozygous variant found in a gene associated with an autosomal recessive condition and/or  
 904 the presence of variants of uncertain significance in genes from the diagnostic list. Numbers  
 905 with asterisks include two participants in the hearing loss cohort with a positive NGS-NBS due  
 906 to likely pathogenic variants in *DSC2* or *F11*, and include one participant in the healthy/well-  
 907 child cohort that was determined to have a positive NGS-NBS screen due to a pathogenic  
 908 variant in *LDLR* associated with familial hypercholesterolemia. NGS-NBS= next-generation  
 909 sequencing newborn screen.

910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925

NC NEXUS participant	NGS-NBS result	Diagnostic (Dx) result	Gene(s)	Disease association with gene (inheritance)	Variant and (predicted protein change)	Zygoty in NC NEXUS participant	Genomic coordinates (hg38) of variant(s)
M001	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.799G>A (p.G267R); c.985A>G (p.K329E)	heterozygous for both variants	chr1:75749509; chr1:75761161
M002	Positive	positive	<i>PAH</i>	PKU (AR)	c.1315+1G>A (p.?); c.782G>A (p.R261Q)	heterozygous for both variants	chr12:102840399; chr12:102852875
M003	Positive	positive	<i>PAH, OTC</i>	PKU (AR), OTC deficiency (XL)	<i>PAH</i> c.1222C>T (p.R408W) and c.896T>G (p.F299C); <i>OTC</i> c.1061T>G (p.F354C)	heterozygous for <i>PAH</i> and <i>OTC</i> variants	chr12:102840493; chr12:102851703; chrX:38421078
M004	Positive	positive	<i>PAH</i>	PKU (AR)	c.1315+1G>A (p.?); c.284_286delTCA (p.I95del)	heterozygous for both variants	chr12:102840399; chr12:102894805-102894807

M005	Positive	positive	<i>PAH</i>	PKU (AR)	c.194T>C (p.I65T); c.814G>T (p.G272*)	heterozygous for both variants	chr12:102894893; chr12:102852843
M006	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E)	homozygous	chr1:75761161
M007	Positive	positive	<i>PAH</i>	PKU (AR)	c.1315+1G>A (p.?); c.842C>T (p.P281L)	heterozygous for both variants	chr12:102840399; chr12:102852815
M008	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E)	homozygous	chr1:75761161
M009	Negative	inconclusive (VUS)	<i>MLYCD</i>	Malonyl-coA decarboxylase deficiency (AR)	c.1013T>C (p.L338P)	homozygous	chr16:83915020
M010	Positive	positive	<i>PAH</i>	PKU (AR)	c.117C>G (p.F39L); c.842C>T (p.P281L)	heterozygous for both variants	chr12:102912842; chr12:102852815
M011	Positive	positive	<i>PAH</i>	PKU (AR)	c.194T>C (p.I65T)	homozygous	chr12:102894893
M012	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E)	homozygous	chr1:75761161
M013	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E)	homozygous	chr1:75761161
M014	Positive	positive	<i>SCL22A5</i>	Renal carnitine transport deficiency (AR)	c.506G>A (p.R169Q)	homozygous	chr5:132384155
M015	Negative	inconclusive (heterozygous variant)	<i>BCKDHA</i>	MSUD type 1A (AR)	c.1312T>A (p.Y438N)	heterozygous	chr19:41424582
M016	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E)	homozygous	chr1:75761161
M017	Positive	positive	<i>ACADM</i>	MCAD deficiency (AR)	c.985A>G (p.K329E); c.199T>C (p.Y67H)	heterozygous for both variants	chr1:75761161; chr1:75732724

928 **Table 2: NGS-NBS and diagnostic findings in the NC NEXUS inborn errors of metabolism**  
 929 **cohort**

930 The NC NEXUS participant column includes “M” (indicating inborn errors of metabolism cohort)  
 931 followed by the participant number. Each row in the table represents one NC NEXUS participant.  
 932 Positive NGS-NBS results indicate a likely pathogenic or pathogenic variant found in the  
 933 newborn screen. A positive diagnostic result indicates a likely pathogenic or pathogenic variant  
 934 in a gene on the inborn errors of metabolism diagnostic list. An inconclusive diagnostic result is  
 935 indicated by any variant of uncertain significance (VUS) finding or a single heterozygous variant  
 936 found in a gene associated with autosomal recessive inborn errors of metabolism. NGS-NBS=  
 937 next-generation sequencing newborn screen; AR= autosomal recessive pattern of inheritance;  
 938 XL= X-linked pattern of inheritance; PKU= phenylketonuria; MCAD deficiency= medium-chain  
 939 acyl-coA dehydrogenase deficiency; MSUD= maple syrup urine disease.

940

941

942

943

944

945

NC NEXUS participant	NGS-NBS result	Diagnostic (Dx) result	Gene	Disease association with gene (inheritance)	Variant and (predicted protein change)	Zygoty in NC NEXUS participant	Genomic coordinates (hg38) of variant(s)
HL003	positive	Positive	<i>SLC26A4</i>	Pendred syndrome (AR)	c.626G>T (p.G209V); c.1151A>G (p.E384G)	heterozygous for both variants	chr7:107674970; chr7:107690125
HL004	negative	inconclusive VUS	<i>MARVELD2</i> ; <i>MYO7A</i>	Deafness 49 (AR); deafness 2 (AR); Usher type 1B (AR)	<i>MARVELD2</i> c.1183-1G>A (p.?); <i>MYO7A</i> c.5824G>A (p.G1942R)	heterozygous for <i>MARVELD2</i> variant; homozygous for <i>MYO7A</i> variant	chr5:69432526; chr11:77207370
HL010	positive	Positive	<i>USH2A</i>	Usher type 2A (AR)	c.1256G>T (p.C419F); c.3686T>G (p.L1229*)	heterozygous for both variants	chr1:216324240; chr1:216199752
HL013	positive	Negative	<i>F11</i>	Factor XI deficiency (AR)	c.1489C>T (p.R497*); c.1608G>C (p.K536N)	heterozygous for both variants	chr4:186286423; chr4:186287715
HL014	positive	Positive	<i>GJB2</i>	Deafness 1A	c.35delG	homozygous	chr13:20189547

				(AR)	(p.G12fs)		
HL016	positive	Positive	<i>USH2A</i>	Usher type 2A (AR)	c.4338_4339delCT (p.C1447fs); c.2299delG (p.E767fs)	heterozygous for both variants	chr1:216190280-216190281; chr1:216247095
HL017	positive	Positive	<i>TECTA</i>	Deafness 8/12 (AD)	c.5597C>T (p.T1866M)	heterozygous	chr11:121168064
HL021	positive	Negative	<i>DSC2</i>	Arrhythmogenic right ventricular dysplasia (ARVD11) (AD)	c.631-2A>G, (p.?)	heterozygous	chr18:31087815
HL022	negative	inconclusive VUS	<i>TMPRSS3</i>	nonsyndromic hearing loss and deafness (AR)	c.208delC (p.H70fs); c.1151T>A (p.M384K)	heterozygous for both variants	chr21:42389043; chr21:42376584
HL025	negative	inconclusive (heterozygous variant)	<i>GJB2</i>	deafness (AR)	c.35delG (p.G12fs)	heterozygous	chr13:20189547
HL026	negative	inconclusive VUS	<i>LOXHD1, CEMIP, MYH14</i>	hearing loss (AR or AD)	<i>LOXHD1</i> c.2914G>A (p.E972K); <i>LOXHD1</i> c.3161C>T (p.T1054M); <i>CEMIP</i> c.58C>T (p.L20F); <i>MYH14</i> c.5942G>C (p.G1981A)	heterozygous for all variants	chr18:46560230; chr18:46559503; chr15:80873937; chr19:50309744
HL027	negative	inconclusive VUS	<i>SOX10</i>	Waardenburg syndrome (AD)	c.482G>A (p.R161H)	heterozygous	chr22:37978082

946

947

948 **Table 3: Participants in the NC NEUXS hearing loss cohort with positive or inconclusive**  
 949 **findings**

950 The NC NEXUS participant column includes “HL” (indicating hearing loss cohort) followed by  
 951 the participant number. Each row in the table represents one NC NEXUS participant. Positive  
 952 NGS-NBS results indicate a likely pathogenic or pathogenic variant found in the newborn screen.  
 953 A positive diagnostic result indicates a likely pathogenic or pathogenic variant in a gene on the  
 954 hearing loss list. An inconclusive diagnostic result is indicated by any variant of uncertain  
 955 significance (VUS) finding or a heterozygous variant found in a gene associated with an  
 956 autosomal recessive form of hearing loss. NGS-NBS= next-generation sequencing newborn  
 957 screen; AR= autosomal recessive pattern of inheritance; AD= autosomal dominant pattern of  
 958 inheritance.

959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975

NC NEXUS participant	NGS-NBS result	Gene	Disease association with gene (inheritance)	Variant and (predicted protein change)	Zygoty in NC NEXUS participant	Genomic coordinates (hg38) of variant(s)
M003	positive	<i>OTC</i>	OTC deficiency (XL)	c.1061T>G (p.F354C)	heterozygous	chrX:38421078
NB012	positive	<i>LDLR</i>	Familial hypercholesterolemia (AD or AR)	c.502G>A (p.D168N)	heterozygous	chr19:11105408
HL013	positive	<i>F11</i>	Factor XI deficiency (AR)	c.1489C>T (p.R497*), c.1608G>C (p.K536N)	heterozygous for both variants	chr4:186286423; chr4:186287715
HL021	positive	<i>DSC2</i>	Arrhythmogenic right ventricular dysplasia (ARVD11) (AD)	c.631-2A>G (p.?)	heterozygous	chr18:31087815

976 **Table 4: Other actionable findings in the NC NEXUS NGS-NBS**

977 The NC NEXUS participant column includes “M” (indicating inborn errors of metabolism cohort),  
978 “HL” (indicating hearing loss cohort) or “NB” (indicating well-child cohort) followed by the  
979 participant number. Each row in the table represents one NC NEXUS participant. Other  
980 actionable findings are indicated by variants found in the NGS-NBS that are associated with a  
981 disorder not previously known in the NC NEXUS participant. NGS-NBS= next-generation  
982 sequencing newborn screen; XL= X-linked inheritance pattern; AR= autosomal recessive  
983 pattern of inheritance; AD= autosomal dominant pattern of inheritance.  
984



